drugset / Trial / NCT00296478

Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)

NCT00296478

Phase 3 Completed 1211 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

This multicenter, randomized, open-label study will be performed in approximately 990 healthy females undergoing IVF. Each study center will follow their study center standard practice for IVF unless otherwise noted in this protocol. The study centers will be provided with the medications for down regulation, stimulation and ovulation induction. The subjects will be randomized to study medication on the day of oocyte retrieval or the day following and will continue treatment for up to 10 weeks. The subjects with a confirmed pregnancy will be required to return to the clinic several times during the course of the 10 week treatment period for serum pregnancy tests and transvaginal ultrasounds to monitor the pregnancy.

Timeline

Start
2005-07
Primary completion
2006-04
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Progesterone Other / unclassified 8 % Other
Comparator Progesterone Other / unclassified 100 mg Other

Indications